Clinical Trial

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B) a single dose of combined drospirenone and ethinyl estradiol. The study will be conducted in adult participants with advanced malignancies for whom no standard or curative treatment options are available.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-06-18
notable Trial sites expanded: 0 -> 3 locations 2026-06-18
notable Primary completion moved earlier: 2029-11-15 -> 2028-03-09 2026-04-03
minor Completion moved earlier: 2029-12-14 -> 2028-04-07 2026-04-03
Trial Details
NCT Number NCT07340190
Lead Sponsor Novartis Pharmaceuticals
Conditions Advanced Malignancies
Enrollment 24 participants
Start Date 2026-06-12
Primary Completion 2028-03-09 (estimated)
Study Completion 2028-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-09